Today, AstraZeneca's Q3 figures were released stating that its COVID-19 Vaccine revenue reached $1.05bn in revenue.
To Airfinity subscribers this wasn’t a surprise as this was just 1% ($8m) off our official forecasts available through our platform. To put this into context, the analyst consensus predicted a more cautious $739m, which turned out to be $311m (30%) below the final amount.
The future of the COVID-19 vaccine market has an enormous impact on the involved companies and the industry as a whole.
We are offering a free 30 minute Q&A with a specialised vaccine analyst. You can request a session via our website: https://www.airfinity.com/covid-book-demo
To view our full 2022 COVID-19 Vaccine Revenue Forecast download for free here.